ArticlePhysiological research2026
Platelet Count and Platelet Indices as Predictive Markers of COVID-19 Mortality.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to analyze changes in platelet count and function in hospitalized COVID-19 patients and compare them with non-COVID-19 patients, focusing on the association between platelet indices and mortality beyond the known link between neutrophil-to-lymphocyte ratio (NLR) and COVID-19 severity. The study sample consisted of 572 patients, out of which 472 were hospitalized with COVID-19 infection from 15th October 2021 to 30th April 2022 in Louis Pasteur University Hospital Kosice, Slovak Republic and 100 represented the control group without COVID-19 infection. COVID-19 positive patients (n=472) had significantly larger size of platelets (MPV 9.2+/-1.4 vs. 8.8+/-1.2, p=0.002) and therefore a higher percentage of platelets larger than 12 fl (P-LCR 33.7 % vs. 24.8 %, p=0.002) than patients in the control group (non-COVID19). The statistically significant relationship was between mortality in patients with COVID-19 infection (n=122) and the larger size of the platelets (MPV), higher platelet large cell ratio, (P-LCR), higher PLT/MPV ratio, higher platelet distribution width to plateletcrit ratio (PDW/PCT), higher neutrophil-to-lymphocyte ratio (NLR) (p<0.001, respectively) and lower platelet count (PLT) and lower plateletcrit (PCT) (p=0.006; p=0.028; respectively). In multivariable logistic regression analysis, a significant positive correlation between mortality, MPV (OR 2.29; 95 % CI 1.70-3.08, p<0.001) and age (OR 1.06; 1.03-1.08, p<0.001) was observed. When NLR was included into this model, MPV was stronger predictor of mortality (OR 2.48; 95 % CI 1.79-3.43, p<0.001) compared to NLR (OR 1.06; 95 % CI 1.03-1.08, p<0.001) and age (OR 1.04; 95 % CI 1.02-1.07, p<0.001). MPV is a strong and independent predictor of mortality in hospitalized COVID-19 patients, demonstrating superior prognostic value compared to established association between neutrophil-to-lymphocyte ratio (NLR) and COVID-19 severity. As a simple and routinely available parameter from standard blood count, MPV may serve as a practical and accessible tool for early risk stratification in the clinical management of COVID-19. Key words Platelets " COVID-19 " Mean platelet volume " Neutrophil to lymphocyte ratio " Mortality.
Indexed as
Identifiers
41811701PMC13128002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.